1. The effect of indapamidevs. bendroflumethiazide for primary hypertension: a systematic review
- Author
-
Filippo Pigazzani, Thomas M. MacDonald, Robert W. V. Flynn, and Tatiana V. Macfarlane
- Subjects
medicine.medical_specialty ,Blood Pressure ,Review ,Coronary Artery Disease ,Placebo ,030226 pharmacology & pharmacy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Bendroflumethiazide ,030212 general & internal medicine ,Diuretics ,Stroke ,Randomized Controlled Trials as Topic ,Pharmacology ,business.industry ,Indapamide ,medicine.disease ,Survival Analysis ,Confidence interval ,Treatment Outcome ,Blood pressure ,Relative risk ,Hypertension ,business ,medicine.drug - Abstract
The aims of the current review were to compare the efficacy of monotherapy with bendroflumethiazide vs. indapamide on mortality, cardiovascular outcomes, blood pressure, need for intensification of treatment and treatment withdrawal. Two authors independently screened the results of a literature search, assessed the risk of bias and extracted relevant data. Randomized clinical trials of hypertensive patients of at least a 1‐year duration were included. When there was disagreement, a third reviewer was consulted. Risk ratio (RR) and mean differences were used as measures of effect. Two trials comparing bendroflumethiazide against placebo, one comparing indapamide with placebo and three of short duration directly comparing indapamide and Bendroflumethiazide, were included. No statistically significant difference was found between indapamide and bendroflumethiazide for all deaths [RR 0.82; 95% confidence interval (CI) 0.57, 1.18], cardiovascular deaths (RR 0.82; 95% CI 0.55, 1.20), noncardiovascular deaths (0.81; 95% CI 0.54, 1.22), coronary events (RR 0.73; 95% CI 0.30, 1.79) or all cardiovascular events (RR 0.89; 95% CI 0.67, 1.18). Indapamide performed worse for stroke (RR 2.21; 95% CI 1.19, 4.11), even though a reduction in RR compared with placebo was observed in both groups. There was no statistically or clinically significant difference between indapamide and bendroflumethiazide in blood pressure reduction (mean absolute difference
- Published
- 2018